華大基因(300676.SZ)擬向禾沐基因增資3000萬元 助力打造地中海貧血疾病“篩診治”閉環解決方案
格隆匯8月12日丨華大基因(300676.SZ)公佈，公司於2022年8月11日召開第三屆董事會第九次會議，審議通過了《關於向深圳市禾沐基因生物技術有限責任公司增資暨關聯交易的議案》，同意公司對深圳市禾沐基因生物技術有限責任公司(簡稱“禾沐基因”或“目標公司”)增資。
同日，公司與目標公司、深圳華大基因藥業投資有限公司、深圳華大生命科學研究院、深圳市禾沐同行科技合夥企業(有限合夥)、深圳市華大松禾生科一號私募創業投資基金合夥企業(有限合夥)、劉超簽署了《關於深圳市禾沐基因生物技術有限責任公司之投資協議》，基於業務發展需要，公司以自有資金3000萬元出資認購目標公司416.6667萬元註冊資本，其餘價款2583.3333萬元作為溢價計入目標公司資本公積。
目標公司完成上述交易後，其註冊資本將由2777.7778萬元增至3194.4445萬元。其中，公司將持有禾沐基因的註冊資本416.6667萬元，佔禾沐基因的股權比例為13.04%。該次交易中，目標公司現有其他股東均已放棄相應的優先認購權。
公司地中海貧血基因檢測系列產品主要為地中海貧血的防控和治療提供檢測依據，禾沐基因專注於基因治療載體和基因改造技術的研發與應用，為地中海貧血患者提供基因治療解決方案，管理團隊在相關領域積累了較豐富經驗，主要產品在臨牀應用方面已取得積極成果。
公司該次通過對禾沐基因增資，加強與其合作，充分發揮交易雙方在地貧篩查和地貧基因治療領域的協同效應，有助於在公司原有的地貧基因檢測產品基礎上打造地中海貧血疾病“篩診治”閉環解決方案，推動公司地中海貧血疾病防控業務發展的同時積極探索地中海貧血疾病領域一體化診療路徑，助力地貧可防可控可治癒目標的實現。該次增資事項符合公司的長期發展戰略，有利於深化拓展公司在單基因遺傳病領域的戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
